Discover G4X

High throughput in-situ spatial sequencing for transcriptomic and proteomic analysis from FFPE samples at subcellular resolution.

A New Era Of Multiomic Discovery with

Spatial Sequencing

Uncover new biological insights with multiomic in-situ sequencing and imaging from a single FFPE section.

Direct-Seq

Direct sequencing of RNA at subcellular resolution.

Direct Sequencing Layer

Transcriptomics

Barcode-free profiling of hundreds of RNA gene transcripts with high sensitivity and specificity.

Transcriptomics Layer

Proteomics

Image dozens of proteins at high resolution.

Proteomics Layer

Fluorescent H&E

Visualize tissue morphology to connect to standard histology.

Fluorescent Layer

On the same FFPE section

Profile

Hundreds of RNA Genes

Profile of Hundreds of RNA Genes
Image

Dozens of Proteins 

Image of dozens of proteins
Visualize

Fluorescent H&E

Fluorescent H&E

Expansive Imaging area

40 cm² imaging area

Breakthrough optical technology for rapid sample scanning at more than 2 billion pixels per second.

G4X sequencer system comparison
G4X Spatial Sequencer

UNPARALLELED SCALE & FLEXIBILITY

24 FFPE samples / run

Expansive imaging area equates to more tissue section regions of interest per run that can be divided across 4 spatial flow cells with flexible configurations.

10x17mm FFPE Sections

Flow Cell 1

Flow Cell 2

Flow Cell 3

Flow Cell 4

UNPARALLELED SCALE & FLEXIBILITY

40 FFPE samples / run

Expansive imaging area equates to more tissue section regions of interest per run that can be divided across 4 spatial flow cells with flexible configurations.

10x10mm FFPE Sections

Flow Cell 1

Flow Cell 2

Flow Cell 3

Flow Cell 4

UNPARALLELED SCALE & FLEXIBILITY

128 FFPE samples / run

Expansive imaging area equates to more tissue section regions of interest per run that can be divided across 4 spatial flow cells with flexible configurations.

4x4mm FFPE Sections

Flow Cell 1

Flow Cell 2

Flow Cell 3

Flow Cell 4

Rapid Turn-around-time

3 Days Sample-to-Discovery

Streamlined tissue preparation and automated amplification combined with rapid imaging, fluidics and high-speed chemistry.

Leading In-Situ Systems

4-16 Days

G4X Spatial Sequencer

3 Days

 

Simple tissue transfer and placement

Specialized tool for simultaneous FFPE section transfer and precise placement on flow cell.

Streamlined 2-day workflow

Simple protocols for sample preparation and integrated readout for RNA, Proteins, and fluorescent H&E.

Single-day run time

Image up to 40 cm² in a single run.

Accelerated on-board analysis

Real-time image processing and secondary analysis.

Unmatched Throughput

20X more samples / week

Scaling tomorrow’s multi-dimensional studies with more samples and more sections for a comprehensive view of tissue biology.

Leading In-Situ Platforms

Runs / Week

Samples / Run

G4X Spatial Sequencer

Runs / Week

Samples / Run

Cost Effective

½ the cost, proteomics included

Breaking barriers for spatial multiomic analysis to help accelerate spatial biology’s translational impact on human health.
Cost/Sample

Two Technologies. One Singular Platform.

Two Technologies.
One
Singular Platform.

G4X combines the power of high-throughput in-situ spatial multiomics with the capabilities of the world’s most powerful benchtop sequencing platform.

Next-Gen Sequencing

Flexible

4 Flow Cells, 16 Lanes

Fast

Daily Sequencing

Powerful

480 Gb and 1.6 B reads/day

Spatial Sequencing

Multiomic

RNA, Protein, H&E

Fast

3-Day Sample-to-Discovery

High-Throughput

20x More Samples/Week

Start Today

Early Adopter Package Available

  • G4 Sequencing Platform and 1-Year Warranty
  • G4X Spatial Sequencer Upgrade
  • G4X Training and 1-Year Extended Warranty
  • Free Spatial Sequencing Services ($50k value)
  • Free G4X Starter Reagents ($50k value)

Up to $700,000 in value

$400,000 with purchase in Q1

$450,000 with purchase in Q2

$500,000 with purchase in Q3

Or

Buy a G4 now at $295,000 and lock in a discounted G4X upgrade package.

UPGRADES STARTING Q4 2024

Protein, transcript and fH&E readout of kidney tumor FFPE serial sections (10x10mm). Data generated on a single flow cell.
Product in Development.  For Research Use Only.

*Limited time offer. Offer good while supplies last. Offer is non-transferrable and may not be resold. We reserve the right to modify or cancel the offer at any time. Offer may not be combined with other offers. Shipping charges and taxes may apply to the full value of discounted and free promotional items. If the offer has a minimum purchase requirement, taxes, and shipping and handling, do not apply when determining the minimum purchase amount. If any of the products or content related to an offer are returned, your refund will equal the amount you paid for the product or content, subject to applicable refund policies. If you violate any of the offer terms, the offer will be invalid. This promotion or offer is valid only within the dates as stated.  We reserve the right to cancel any order due to unauthorized, altered, or ineligible use of a discount. Promotions and discounts cannot be applied to previous purchases, taxes, shipping or processing charges or combined with any other discounts or promotions.  Other restrictions may apply. Offers only apply to the United States unless otherwise noted.

Get Started with G4X

Please provide your information and a member of the Singular Genomics team will be in contact with additional G4X details.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note